Coronavirus (COVID-19)
Learn more
May 09, 2017
Sponsor: GRAIL, Inc.
Number: GRAIL
This is a prospective, multi-center, observational study with collection of de-identified bio specimens and clinical data from at least 10,000 participants from clinical networks in the United States. A prospective study watches for outcomes, such as the development of a disease, during the study period and relates this to other factors such as suspected risk or protection factor. The study will enroll at least 7000 cancer subjects with multiple solid tumor types (the CANCER arm) and at least 3000 representative subjects without a clinical diagnosis of cancer (the NON-CANCER arm). Cancer subjects with a new diagnosis and no prior systemic therapy will be recruited. Clinical data relevant to cancer status are collected from all participants and their medical record at baseline, and subsequently from the medical record at intermittent future time points, at least annually for up to 5 years. The study test(s) to be used in this protocol are next generation sequencing (NGS)-based assay(s) that are under investigation and development at GRAIL.
Who’s eligible:
Cancer group:
Either of the following:
Has or will have a medically obtained pathological tumor specimen from core needle or surgical biopsy and/or surgical resection, within 4 weeks (28 days) of study blood draw and pre-treatment.
Non-Cancer group:
Available at: The Hospital of Central Connecticut and Hartford Hospital.
Referral Line: 860.972.4700
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.